搜索 联络表
This page is available in multiple languages
Select Language

EnterNext welcomes TxCell on Euronext's market in Paris

Back

14/04/2014

Playing this video will load a content from YouTube, a service of Google LLC. For information on how Google may use your data, see the Google privacy policy.


Accept cookies

Damian Marron, CEO of TxCell, opens the European trading day in Paris.

TxCell is a biotechnology group that specializes in developing customized cell immunotherapy using antigen-specific regulatory T cells (Ag-Tregs) and for the treatment of severe chronic inflammatory and autoimmune diseases.
At the end of 2013, TxCell has a portfolio of 4 products including 1 in phase II of development (Ovasave; treatment of the Crohn disease), 1 in phase I/II of development (Col-Treg; treatment of autoimmune uveitis), 1 in phase of preclinical development (Myelin-Treg; treatment of the progressive forms of multiple sclerosis) and 1 in research phase (HSP60-Treg).